MedTrace Logo

Comparing 3 Schedules of Alimta Plus Gemzar

NCT00034606 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-07-19

No results posted yet for this study

Summary

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neoplasms

Interventions

DRUG

Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00034606 on ClinicalTrials.gov